Sanofi/GSK’s Vidprevtyn Is Fifth COVID-19 Vaccine Candidate Under Rolling Review at EMA
Sanofi and GSK are way behind in the COVID-19 vaccine race and the start of a rolling review of Vizprevtyn at the European Medicines Agency is an important step.
You may also be interested in...
Sanofi and GSK, which are in the middle of Phase III global trials for their COVID-19 vaccine candidate, plan to test the contender against all variants of concern including the highly contagious Delta variant, Scrip has learned. Meanwhile, Pfizer/BioNTech is looking at a booster to combat lower efficacy/effectiveness against this variant.
GSK’s share price is down by 15% since Walmsley took over as CEO, but major investors are said to be resisting calls for a radical re-think in its strategy.
In the first half of 2021, just six requests from companies seeking accelerated assessment of their planned EU marketing authorization applications were granted; 11 were rejected. The outcomes of five decided on in July and August are still unknown.